Replimune Group (NASDAQ:REPL) Stock Jumps 8.3% – Time to Buy?

Replimune Group, Inc. (NASDAQ:REPL)’s stock price shot up 8.3% on Monday. The stock traded as high as $19.09 and last traded at $19.0740. 4,814,670 shares were traded during mid-day trading, an increase of 11% from the average session volume of 4,332,466 shares. The stock had previously closed at $17.61.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on REPL. Wolfe Research raised Replimune Group to an “outperform” rating in a research report on Tuesday, August 4th. JPMorgan Chase & Co. upped their price objective on Replimune Group from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Wednesday, August 26th. Piper Sandler raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Friday, July 31st. Wedbush upgraded shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price objective on the stock in a research note on Friday, August 7th. Finally, Leerink Partners lifted their price target on Replimune Group from $19.00 to $31.00 and gave the company an “outperform” rating in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $14.33.

Replimune Group Trading Up 10.7%

The company has a market cap of $1.85 billion, a price-to-earnings ratio of -6.99 and a beta of 0.93. The company has a quick ratio of 6.90, a current ratio of 7.11 and a debt-to-equity ratio of 0.59. The firm has a 50 day moving average price of $13.58 and a two-hundred day moving average price of $9.35.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Wednesday, October 28th. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.24. As a group, equities analysts forecast that Replimune Group, Inc. will post -2.61 earnings per share for the current year.

Insider Activity at Replimune Group

In other Replimune Group news, CEO Sushil Patel sold 39,341 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $510,252.77. Following the transaction, the chief executive officer directly owned 708,151 shares of the company’s stock, valued at approximately $9,184,718.47. This trade represents a 5.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Emily Hill sold 11,448 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $12.97, for a total transaction of $148,480.56. Following the completion of the transaction, the chief financial officer directly owned 225,108 shares in the company, valued at approximately $2,919,650.76. The trade was a 4.84% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 79,124 shares of company stock worth $1,038,364 over the last quarter. 5.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Replimune Group

Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. bought a new position in Replimune Group in the 2nd quarter valued at $99,171,000. Montanova Capital LLC lifted its position in shares of Replimune Group by 4.0% during the second quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock worth $48,595,000 after acquiring an additional 168,000 shares in the last quarter. Opaleye Management Inc. bought a new position in Replimune Group in the 2nd quarter worth about $15,332,000. Dimensional Fund Advisors LP boosted its position in shares of Replimune Group by 1.9% in the first quarter. Dimensional Fund Advisors LP now owns 1,140,099 shares of the company’s stock valued at $8,719,000 after acquiring an additional 20,742 shares during the period. Finally, EcoR1 Capital LLC purchased a new stake in shares of Replimune Group in the first quarter worth $7,650,000. Hedge funds and other institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.